You are here: Home » Markets » News
Business Standard

Sensex ends 330 pts higher, Nifty above 10,550; IT, pharma, realty gain

All that happened in the markets today.

Topics
Markets

SI Reporter  |  New Delhi 

The indices ended higher on Thursday after the market heavyweights such as Infosys gained over 2%. The S&P BSE Sensex gained over 500 points to 34634 levels before trimming gains. In broader markets, Nifty50 index hit an intra-day high of 10,637 levels. The S&P BSE Sensex ended at 34,413, up nearly 330 points while the broader Nifty50 index settled at 10,576, up around 100 points. Among other index stocks, Sun Pharma, Dr. Reddy's, State Bank of India, Axis Bank and HDFC gained between 1.5% to 6.1%. Shares of Cipla surged as much as 6.85% after the ...

MONTHLY STAR

Business Standard Digital

Business Standard Digital Monthly Subscription
199.00  
subscribe
Complete access to the premium product
Convenient - Pay as you go
Pay using Amex/Master/VISA Credit Cards and VISA Debit Cards Only
Auto renewed (subject to your card issuer's permission)
Cancel any time in the future
Requires personal information

What you get?

ON BUSINESS STANDARD DIGITAL

  • Unlimited access to all the content on any device through browser or app.
  • Exclusive content, features, opinions and comment – hand-picked by our editors, just for you.
  • Pick 5 of your favourite companies. Get a daily email with all the news updates on them.
  • Track the industry of your choice with a daily newsletter specific to that industry.
  • Stay on top of your investments. Track stock prices in your portfolio.
  • 18 years of archival data.

NOTE :

  • The product is a monthly auto renewal product.
  • Cancellation Policy: You can cancel any time in the future without assigning any reasons, but 48 hours prior to your card being charged for renewal. We do not offer any refunds.
  • To cancel, communicate from your registered email id and send the email with the cancellation request to assist@bsmail.in. Include your contact number for speedy action. Requests mailed to any other ID will not be acknowledged or actioned upon.

SMART ANNUAL

Business Standard Digital
Subscribe Now and get 12 months Free

Business Standard Premium Digital - 12 Months + 12 Months Free
1799.00
subscribe
Subscribe for 12 months and get 12 months free.
Single Seamless Sign-up to Business Standard Digital
Convenient - Once a year payment
Pay using an instrument of your choice -all Credit and Debit Cards, Net Banking, Payment Wallets, and UPI
Exclusive Invite to select Business Standard events

What you get

ON BUSINESS STANDARD DIGITAL

  • Unlimited access to all content on any device through browser or app.
  • Exclusive content, features, opinions and comment - hand-picked by our editors, just for you.
  • Pick 5 of your favourite companies. Get a daily email with all the news updates on them.
  • Track the industry of your choice with a daily newsletter specific to that industry.
  • Stay on top of your investments. Track stock prices in your portfolio.

NOTE :

  • The monthly duration product is an auto renewal based product. Once subscribed, subject to your card issuer's permission we will charge your card/ payment instrument each month automatically and renew your subscription.
  • In the Annual duration product we offer both an auto renewal based product and a non auto renewal based product.
  • We do not Refund.
  • No Questions asked Cancellation Policy.
  • You can cancel future renewals anytime including immediately upon subscribing but 48 hours before your next renewal date.
  • Subject to the above, self cancel by visiting the "Manage My Account“ section after signing in OR Send an email request to assist@bsmail.in from your registered email address and by quoting your mobile number.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Sensex ends 330 pts higher, Nifty above 10,550; IT, pharma, realty gain

Nifty top gainer: Nifty Pharma Index

Sensex ends 330 pts higher, Nifty above 10,550; IT, pharma, realty gain

Markets Check Index Current Pt. Change % Change   S&P BSE SENSEX 34,413.16 +330.45 +0.97   S&P BSE SENSEX 50 11,026.92 +108.24 +0.99   S&P BSE SENSEX Next 50 34,632.14 +596.51 +1.75   S&P BSE 100 10,958.39 +120.39 +1.11   S&P BSE Bharat 22 Index 3,712.43 +12.53 +0.34 (Source: BSE)

Sensex ends 330 pts higher, Nifty above 10,550; IT, pharma, realty gain

Sectoral Trend

Sensex ends 330 pts higher, Nifty above 10,550; IT, pharma, realty gain

Sensex heatmap

Sensex ends 330 pts higher, Nifty above 10,550; IT, pharma, realty gain

Markets at close   Benchmark indices rose more than 1 per cent on Thursday after seven consecutive sessions of declines, as market heavyweights such as Infosys recovered and as drug maker Cipla gained on solid earnings.   The S&P BSE Sensex ended at 34,413, up nearly 330 points while the broader Nifty50 index settled at 10,576, up around 100 points.  

Sensex ends 330 pts higher, Nifty above 10,550; IT, pharma, realty gain

Pharma shares in focus; Cipla, Sun Pharma surge over 5%   Shares of pharmaceutical companies were in focus with the Nifty Pharma index gaining nearly 4% on back of strong rally in Cipla and Cadila Healthcare post their December quarter results.   Among the pharma index, Cipla and Sun Pharmaceutical Industries have rallied more than 5% each, while Cadila Healthcare, Dr Reddy’s Laboratories and Divi’s Laboratories up in the range of 2% to 4% on the National Stock Exchange (NSE). READ MORE

Sensex ends 330 pts higher, Nifty above 10,550; IT, pharma, realty gain

Earnings impact Balrampur Chini shares declined 3 per cent as profit in quarter ended December 2017 fell sharply by 65 per cent to Rs 61.4 crore from Rs 175.2 crore in year-ago, impacted by disappointing operational performance.   Revenue from operations increased 6.9 per cent to Rs 1,001.9 crore in Q3FY18, compared to Rs 937 crore in same period last year.

Sensex ends 330 pts higher, Nifty above 10,550; IT, pharma, realty gain

HeidelbergCement India surges 12% on strong Q3 results   HeidelbergCement India surged 12% to Rs 168 on BSE in afternoon deals after the company reported net profit of Rs 318 million for the quarter ended December 2017 (Q3FY18), on back of higher sales.   It had posted a net loss of Rs 36 million in the same quarter last fiscal.   Net sales during the quarter rose 24.8% to Rs 4,839 million against Rs 3,878 million in the corresponding quarter of previous year. READ MORE

Sensex ends 330 pts higher, Nifty above 10,550; IT, pharma, realty gain

Market Check Index Current Pt. Change % Change   S&P BSE SENSEX 34,399.70 +316.99 +0.93   S&P BSE SENSEX 50 11,017.53 +98.85 +0.91   S&P BSE SENSEX Next 50 34,523.25 +487.62 +1.43   S&P BSE 100 10,945.09 +107.09 +0.99   S&P BSE Bharat 22 Index 3,712.15 +12.25 +0.33 (Source: BSE)

Sensex ends 330 pts higher, Nifty above 10,550; IT, pharma, realty gain

Prestige, HDFC Capital to invest Rs 25 bn for affordable housing projects Realty firm Prestige Estates Projects has partnered HDFC's arm HDFC Capital Advisors to set up Rs 25 billion (Rs 2,500 crore) fund to develop affordable and mid-income housing projects across the country.   This platform would enable Prestige group to develop projects worth Rs 100 billion (Rs 10,000 crore). READ MORE

Sensex ends 330 pts higher, Nifty above 10,550; IT, pharma, realty gain

Sectoral Trend

First Published: Thu, February 08 2018. 15:31 IST
RECOMMENDED FOR YOU

Sensex ends 330 pts higher, Nifty above 10,550; IT, pharma, realty gain

All that happened in the markets today.

The indices ended higher on Thursday after the market heavyweights such as Infosys gained over 2%. The S&P BSE Sensex gained over 500 points to 34634 levels before trimming gains. In broader markets, Nifty50 index hit an intra-day high of 10,637 levels. The S&P BSE Sensex ended at 34,413, up nearly 330 points while the broader Nifty50 index settled at 10,576, up around 100 points. Among other index stocks, Sun Pharma, Dr. Reddy's, State Bank of India, Axis Bank and HDFC gained between 1.5% to 6.1%. Shares of Cipla surged as much as 6.85% after the ...

image
Business Standard
177 22